Effect of crisaborole topical ointment, 2%, on atopic dermatitis–associated pruritus: an extended analysis of 2 phase 3 clinical trials
Itch · 2018
DOI: 10.1097/itx.0000000000000012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Itch, 2018. Verfasst von Gil Yosipovitch und 10 weiteren Autor:innen. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Pruritus is an essential feature of atopic dermatitis (AD) and is widely considered the most distressing symptom. Crisaborole ointment is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild to moderate AD. The efficacy of crisaborole for AD-associated pruritus was assessed in 2 phase 3 trials using the Severity of Pruritus Scale (SPS). Post hoc validation of the SPS identified that 1 SPS observation provided inadequate test-retest reliability. Therefore, extended analyses were conducted using at least 2 SPS observations for robust assessment of pruritus in the phase 3 crisaborole trials.
Methods
Data were analyzed from 2 identically designed, vehicle-controlled, double-blind, phase 3 trials designed to investigate the efficacy and safety of crisaborole in AD patients aged 2 years and above (AD-301: NCT02118766; AD-302: NCT02118792). At least 2 SPS observations were averaged for acceptable test-retest reliability.
Results
At least 2 baseline observations were available for 569 patients in AD-301 and 561 patients in AD-302. Median time to pruritus improvement (SPS score ≤1 with at least 1-point improvement from baseline) was shorter with crisaborole than with vehicle (AD-301: 5.0 vs. 10.0 d, P =0.0003; AD-302: 6.0 vs. 9.0 d, P =0.0087). At week 4, more crisaborole-treated patients than vehicle-treated patients experienced pruritus improvement (AD-301: 37% vs. 21%, P
Zitieren
APA
Yosipovitch, G., Simpson, E. L., Tan, H., Gerber, R. A., Luger, T., Ständer, S., Tom, W. L., Cappelleri, J. C., Bushmakin, A. G., Ports, W. C., & Tallman, A. M. (2018). Effect of crisaborole topical ointment, 2%, on atopic dermatitis–associated pruritus: an extended analysis of 2 phase 3 clinical trials. Itch. https://doi.org/10.1097/itx.0000000000000012
Vancouver
Yosipovitch G, Simpson EL, Tan H, Gerber RA, Luger T, Ständer S, et al. Effect of crisaborole topical ointment, 2%, on atopic dermatitis–associated pruritus: an extended analysis of 2 phase 3 clinical trials. Itch. 2018. doi:10.1097/itx.0000000000000012
BibTeX
@article{Yosipovitch2018,
author = {Yosipovitch, Gil and Simpson, Eric L. and Tan, Huaming and Gerber, Robert A. and Luger, Thomas and Ständer, Sonja and Tom, Wynnis L. and Cappelleri, Joseph C. and Bushmakin, Andrew G. and Ports, William C. and Tallman, Anna M.},
title = {Effect of crisaborole topical ointment, 2%, on atopic dermatitis–associated pruritus: an extended analysis of 2 phase 3 clinical trials},
journal = {Itch},
year = {2018},
doi = {10.1097/itx.0000000000000012}
}
EUVIMED